CANSINOBIO
Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.
CANSINOBIO
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical Medical Device
Founded:
2009-01-01
Address:
Tianjin, Guangdong, China
Country:
China
Website Url:
http://www.cansinotech.com
Total Employee:
101+
Status:
Active
Contact:
+02225616006
Email Addresses:
[email protected]
Total Funding:
115.97 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Content Delivery Network Google Maps GStatic Google Static Content COVID-19 China Telecom TrustAsia Bootcss
Similar Organizations
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
AVATAMED
Biotechnology, Biopharmaceutical
Bharat Biotech
India's second biggest vaccines company
Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Pilot Biotechnology
Pilot Biotechnology is an industrial biotechnology company engaged in the development, production, and sales of health care products.
Qihan Biotech
Qihan Biotech is a gene-editing organ transplantation technology developer.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
GoldStone
GoldStone investment in Series E - CanSinoBIO
Lilly Asia Ventures
Lilly Asia Ventures investment in Series E - CanSinoBIO
SDIC Fund Management
SDIC Fund Management investment in Series E - CanSinoBIO
Qiming Venture Partners
Qiming Venture Partners investment in Series E - CanSinoBIO
Fortune Capital
Fortune Capital investment in Series E - CanSinoBIO
Gopher Asset Management
Gopher Asset Management investment in Series E - CanSinoBIO
Qiming Venture Partners
Qiming Venture Partners investment in Venture Round - CanSinoBIO
Qiming Venture Partners
Qiming Venture Partners investment in Series C - CanSinoBIO
Lilly Asia Ventures
Lilly Asia Ventures investment in Series C - CanSinoBIO
Lilly Asia Ventures
Lilly Asia Ventures investment in Venture Round - CanSinoBIO
Official Site Inspections
http://www.cansinotech.com Semrush global rank: 2.42 M Semrush visits lastest month: 7.44 K
- Host name: 47.99.161.107
- IP address: 47.99.161.107
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "CanSinoBIO"
康希诺生物 - cansinotech.com
Prof. Liming Li is the Boya Professor and the Dean of School of Public Health and major Epidemic Prevention and Control, Peking University. The Founder Director General of Chinese Center …See details»
康希诺生物
CanSinoBIO is an industry-leading biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research & …See details»
The National Research Council of Canada and CanSino Biologics …
Articles of Association - cansinotech.com
2 Article 6 The registered capital of the Company is RMB247,449,899. Article 7 The chairman of the Board is the Company’s legal representative. Article 8 The Company is a perpetual joint …See details»
CanSino Biologics - Wikipedia
CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua. In July 2018, it filed an application to list on the Hong Kong Stock Exchange. It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017. In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR marke…See details»
CanSinoBIO - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +02225616006 Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and …See details»
CanSino Biologics Inc.康希诺生物 | LinkedIn
CanSino Biologics Inc. (CanSinoBIO, SHSE: 688185, HKEX:06185) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of …See details»
CanSino Biologics Inc Company Profile - Overview - GlobalData
Website www.cansinotech.com.cn Telephone 86 22 58213766. No of Employees 2,191. Industry Pharmaceuticals and Healthcare. Ticker Symbol & Exchange 6185 (HKG) Revenue (2022) …See details»
CanSino Biologics - Overview, News & Similar companies
Www.cansinotech.com. Revenue $49.3 Million. Industry Manufacturing General Manufacturing . Most Recent Scoops. Apr 25 2022. Project. Aug 3 2020. Initial Public Offering (IPO), a …See details»
The National Research Council of Canada and CanSino ... - BioSpace
May 12, 2020 One of only a handful of vaccine candidates currently in human clinical trials in the world to begin initial evaluation in Canada. MONTRÉAL, May 12, 2020 /CNW/ - The National …See details»
康希诺生物 CanSinoBIO - cansinotech.com
巢守柏，2018年5月加入康希诺生物公司并任 执行董事及 首席运营官，主要负责本公司的日常运营管理及战略发展。 此外，巢守柏博士亦负责本公司的生产中心及质量中心。在加入康希诺之 …See details»
CanSino Biologics - Craft
CanSino Biologics is a biotechnology company dedicated to the R&D, manufacturing, and commercialization of vaccine products for human use. CanSino’s mission is to develop high …See details»
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO …
TIANJIN, China, May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has …See details»
CanSinoBIO Kicks-off the Polio VLP Vaccine Cooperation
Dec 4, 2023 CanSinoBIO has been actively participating in the World Health Organization (the WHO) polio eradication strategy to eliminate the disease, and has been focusing on the needs …See details»
康希诺生物 - cansinotech.com
Address: 401-420, 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District, Tianjin, PRC Hong Kong: Room 1901, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay …See details»
CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of …
TIANJIN, April 3, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: 688185, HKEX: 06185) today announced that the National Medical Products …See details»
康希诺生物 - cansinotech.com
Our R&D center has a floor space of more than 17,000 square meters, with various advanced labs. •Over 20,000 square meters •Advanced laboratory facilities •World-class R&D equipment。See details»
CanSinoBIO Kicks-off the Polio VLP Vaccine Cooperation
Dec 4, 2023 CanSinoBIO has been actively participating in the World Health Organization (the WHO) polio eradication strategy to eliminate the disease, and has been focusing on the needs …See details»
CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of
TIANJIN, April 3, 2022 /CNW/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration of …See details»
康希诺生物 - cansinotech.com
Feb 24, 2021 As of today, it has established a robust pipeline of 16 vaccines preventing 13 diseases, including a globally innovative Ebola virus vaccine (Adenovirus Type 5 Vector) …See details»